N-methyl-D-aspartate (NMDA) receptors have been implicated in L-Dopa-induced
dyskinesias (LID) in Parkinson's disease patients, but the use of antagonists that directly …

This study assessed striatal N-methyl-D-aspartate (NMDA) glutamate receptors of 1-methyl 4-
phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) monkeys with levodopa (L-DOPA)-induced …

Alterations of striatal glutamate receptors are believed to be responsible, at least in part, for
the pathogenesis of l-dopa-induced dyskinesias (LID). To evaluate whether co …

Amantadine has been shown to displace [3 H] MK 801 from its binding site on the NMDA
receptor. We have therefore studied the motor effects of amantadine in normal and 24h …

An increasing body of experimental evidence demonstrates that the glutamatergic system is
involved in the genesis of l-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia …

Amantadine and dextromethorphan suppress levodopa (l-DOPA)-induced dyskinesia in
Parkinson's disease patients and abnormal involuntary movements (AIMs) in the 6 …

Dopamine-replacement therapy with l-DOPA is still the gold standard treatment for
Parkinson's disease (PD). One drawback is the common development of l-DOPA-induced …

The present study shows that high doses of the non-competitive NMDA antagonist
phencyclidine (PCP) as well as of the competitive NMDA antagonist SDZ EAA494 (D …

The antiparkinsonian and antidyskinetic profile of two N-methyl-d-aspartate (NMDA)
receptor antagonists, a competitive antagonist,(R)-4-oxo-5-phosphononorvaline (MDL …

Long-term l-DOPA treatment for Parkinson's disease (PD) is limited by motor complications,
particularly l-DOPA-induced dyskinesia (LID). A therapy with the ability to ameliorate LID …